IL15 and neoplasm: The anti-tumor activity might be improved by introducing a CD16 transgene, similar to the FT596—the first iPSC-derived CAR-NK cell product that underwent a clinical trial (NCT04245722)—which expressed a high-affinity, non-cleavable CD16 with an IL-15 receptor fusion protein (IL-15/R-hnCD16) [24].